SCHEMBL1839710

SCHEMBL1839710

O=C(Cc1ccccc1)NC1(C(=O)O)CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
HTT P42858 2/20 0.58
ADRB2 P07550 1/20 0.58
EPHX2 P34913 2/20 0.51
CTSB P07858 2/20 0.49
CTSS P25774 2/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
APAF1 O14727 1/20 0.49
TDP2 O95551 1/20 0.49
NSD2 O96028 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.43
CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5102084 0.86 CYP19A1 (0.49) ALDH1A1HTTADRB2MAPTNPC1
SCHEMBL1837653 0.84 CTSB (0.67) ALDH1A1HTTCTSBCTSSMAPT
SCHEMBL6206153 0.84 SMN1; SMN2 (0.47) ALDH1A1HTTADRB2EPHX2MAPT
SCHEMBL23242479 0.83 CNR1 (0.52) ALDH1A1HTTADRB2CTSBCTSS
SCHEMBL1837974 0.83 ALDH1A1 (0.54) ALDH1A1HTTADRB2EPHX2CTSB
SCHEMBL13502664 0.80 CNR2 (0.42) ALDH1A1HTTADRB2CTSBCTSS
SCHEMBL23265261 0.80 GAA (0.51) ALDH1A1HTTADRB2MEN1KMT2A
SCHEMBL13570375 0.79 HTT (0.50) ALDH1A1HTTADRB2EPHX2MAPT
SCHEMBL5110701 0.79 EPHX2 (0.49) ALDH1A1HTTADRB2EPHX2CTSB
SCHEMBL4079580 0.78 LMNA (0.45) ALDH1A1HTTCTSBCTSSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US claimed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 US claimed
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 US disclosed
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 US disclosed
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 US disclosed
CN-101370773-A Cycloalkanecarboxamide derivative and method for producing same SEIKAGAKU KOGYO CO LTD (JP) 2009-02-18 CN disclosed
EP-1975162-A1 OXAZOLONE DERIVATIVE SEIKAGAKU CORPORATION (JP) 2008-10-01 EP disclosed
EP-1972636-A1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 EP disclosed
EP-1972615-A1 CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 EP disclosed
EP-1294679-B1 BETA-AMINO ACID NITRILE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-09-21 EP disclosed
EP-1294679-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-26 EP disclosed
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US disclosed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 US disclosed
WO-2001096285-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors CTSK, CTSH, UACA ALDH1A1 3459/4885HTT 3263/4885ADRB2 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.